RBC Capital Maintains Outperform on Nurix Therapeutics, Raises Price Target to $36

Benzinga · 2d ago
RBC Capital analyst Brian Abrahams maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $33 to $36.